Targeted protein degradation (TPD) using the endogenous Ubiquitin Proteasome System (UPS) represents an ideal drug discovery approach that potentially allows targeting proteins that have proven difficult to access via conventional inhibitor strategies. Plexium has discovered novel monovalent Direct Degraders that, in contrast to bivalent PROTACs, are small molecules designed to bind the target protein and induce its degradation through the recruitment of an E3 ligase complex…